TITLE

Gestational Exposure to Antidepressants and the Risk of Spontaneous Abortion: A Review

AUTHOR(S)
Broy, Perrine; Bérard, Anick
PUB. DATE
January 2010
SOURCE
Current Drug Delivery;Jan2010, Vol. 7 Issue 1, p76
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. Although the relationship between antidepressant use during pregnancy and its adverse effects has been widely investigated, very few studies have evaluated the impact of antidepressant use during pregnancy on the risk of spontaneous abortion. We present an overview of the evidence relating to the association between antidepressant use during gestation and the risk of spontaneous abortion. Methods. We systematically searched PubMed and the reference lists of all relevant articles, including reviews, published in English or French from 1975 through 2009 for studies that examined the association between adverse pregnancy outcomes and gestational exposure to antidepressants with data on spontaneous abortions. Only etiologic studies were considered. Results. Fifteen studies met inclusion criteria. The majority of these were prospective cohort studies on tricyclics antidepressants (TCAs) or selective serotonin reuptake inhibitors (SSRIs) use during pregnancy. Overall, in unadjusted analyses, fluoxetine (OR = 2.0; 95% CI = 1.4 -- 3.0) and bupropion (OR = 4.1; 95% CI = 1.5 -- 11.1) were significantly associated with the risk of spontaneous abortion. However, in adjusted analyses, only paroxetine (OR = 1.7; 95% CI = 1.3 -- 2.3) and venlafaxine (OR = 2.1; 95% CI = 1.3 -- 3.3) were significantly associated with the risk of spontaneous abortion. Conclusions. This review suggests that gestational exposure to antidepressants, especially paroxetine and venlafaxine, can lead to spontaneous abortion.
ACCESSION #
51546791

 

Related Articles

  • Paroxetine/venlafaxine.  // Reactions Weekly;Mar2014, Vol. 1493 Issue 1, p36 

    The article presents case studies of two women aged 38 years and 29 years who developed weight gain while receiving treatment with venlafaxine and paroxetine respectively.

  • Use of antidepressants during pregnancy and the risk of spontaneous abortion. Nakhai-Pour, Hamid Reza; Broy, Perrine; Bérard, Anick // CMAJ: Canadian Medical Association Journal;7/13/2010, Vol. 182 Issue 10, p1031 

    Background: The risk of relapse of depression or the diagnosis of some other psychiatric disorders during pregnancy necessitates the use of antidepressants despite possible adverse effects. Whether such use increases the risk of spontaneous abortion is still being debated. We evaluated the risk...

  • Venlafaxine.  // Reactions Weekly;12/2/2006, Issue 1130, p26 

    The article presents case reports of two neonates who developed seizures following in utero exposure to venlafaxine. It references a study by R. K. Pakalapati et al published in the November 2006 issue of the "Journal of Paediatrics and Child Health." The medical histories of the mothers of the...

  • AE spectrum similar, frequency varies for 2nd-gen antidepressants.  // Reactions Weekly;10/18/2008, Issue 1224, p1 

    The article discusses research on adverse event (AE) profiles of second-generation antidepressants. It references a study by G. Gartlehner et al, published in the volume 31, No. 10 issue of "Drug Safety." The researchers from Austria and the U.S. analysed comparative AE data for 12...

  • Warfarin.  // Reactions Weekly;Jul2015, Vol. 1559 Issue 1, p180 

    An abstract of the article "Prosthetic mitral valve thrombosis in pregnancy: From thrombolysis to anticoagulation," by G. Cardoso and colleagues is presented.

  • Paroxetine.  // Reactions Weekly;10/9/2010, Issue 1322, p23 

    The article describes the case of a 33-year-old male with agoraphobia who developed ecchymoses following treatment with paroxetine, referencing a study published in the August 2010 issue of the journal "Primary Psychiatry."

  • Paroxetine.  // Reactions Weekly;2/13/2010, Issue 1288, p32 

    The article describes a case of elevated carcinoembryonic antigen in a 61-year-old man after receiving paroxetine for a year for the treatment of a depressive episode.

  • Escitalopram/paroxetine.  // Reactions Weekly;2/18/2012, Issue 1389, p22 

    The article describes the case of two women who experienced parkinsonism while receiving treatment with paroxetine or escitalopram.

  • Paroxetine.  // Reactions Weekly;1/28/2012, Issue 1386, p30 

    The article describes the case of a 42-year-old man who developed dysarthria following administration of paroxetine 12.5 milligrams a day (mg/day) for episodes of involuntary and uncontrollable outbursts of laughter.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics